Back to Search
Start Over
Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis.
- Source :
-
Journal of Neuroimmunology . Sep2016, Vol. 298, p79-81. 3p. - Publication Year :
- 2016
-
Abstract
- Rituximab (RTX) has demonstrated efficacy in limiting relapses in myasthenia gravis (MG). We investigated the interest of CD27 + memory B cell monitoring in patients as a biological marker of clinical relapse. Twenty-four patients have been treated with RTX (375 mg/m 2 /week-month as an induction treatment). Maintenance treatment consisted with either systematic treatment every 3 months or only when CD27 + memory B cells were detectable. After the induction treatment, the mean infusions were 1.3/year compared with 4/year. We suggest that RTX administration frequency can be decreased safely by monitoring the re-emerging CD27 + memory B cells. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 01655728
- Volume :
- 298
- Database :
- Academic Search Index
- Journal :
- Journal of Neuroimmunology
- Publication Type :
- Academic Journal
- Accession number :
- 117893200
- Full Text :
- https://doi.org/10.1016/j.jneuroim.2016.07.009